R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis

References

• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Davies A. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Hematology Am Soc Hematol Educ Program. 2017;2017(1):284–294.
   PubMed Web of Science ®Google Scholar
• Mondello P, Mian M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP. Hematol Oncol. 2019;37(4):333–344.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–3537.
   PubMed Web of Science ®Google Scholar
• Higgins JPT TJ, Chandler J, Cumpston M, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane. 2019. http://www.training.cochrane.org/handbook
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–2834.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Lucie Oberic MP, Peyrade F, Maisonneuve H, et al. Sub-cutaneous rituximab-miniCHOP versus sub-cutaneous rituximab-miniCHOP + lenalidomide (R2-miniCHOP) in diffuse large B cell lymphoma for patients of 80 years old or more (SENIOR study). A multicentric randomized phase III study of the lysa. Blood. 2019;134(Supplement_1):352–352.
   Web of Science ®Google Scholar
• Nowakowski G, Hong F, Scott D, et al. Addition of lenalidomide to R‐CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL): first report of ECOG‐ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R‐CHOP. Hematol Oncol. 2019;37(S2):37–38.
   Google Scholar
• Vitolo U, Witzig T, Gascoyne R, et al. ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma. Hematol Oncol. 2019;37(S2):36–37.
   Google Scholar
• Aurer I, Eghbali H, Raemaekers J, et al. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin’s lymphoma-EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). Eur J Haematol. 2011;86(2):111–116.
   PubMed Web of Science ®Google Scholar
• Davies A, Cummin TE, Barrans S, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–662.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Arrowsmith ER, McCleod M, et al. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(1):216–218.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Kolibaba KS, Reeves JA, et al. Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3538–3546.
   PubMed Web of Science ®Google Scholar
• Offner F, Samoilova O, Osmanov E, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–1901.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Pfreundschuh M, Trnĕný M, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99(8):1343–1349.
   PubMed Web of Science ®Google Scholar
• Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–1295.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–1826.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–1867.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist. 2014;19(12):1249–1257.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M, Reljic T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: a systematic review and meta-analysis. Cancer. 2019;125(24):4417–4425.
   PubMed Web of Science ®Google Scholar
• Rozental A, Gafter-Gvili A, Vidal L, et al. The role of maintenance therapy in patients with diffuse large B cell lymphoma: a systematic review and meta-analysis. Hematol Oncol. 2019;37(1):27–34.
   PubMed Web of Science ®Google Scholar
• Laurie H Sehn AGC, Culligan DJ, Gironella M, et al. No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study. Blood. 2018;132(Supplement 1):783–783.
   Web of Science ®Google Scholar
• Qian Shi NS, Flowers C, Ou F-S, et al. Evaluation of Progression-Free Survival (PFS) as a surrogate endpoint for Overall Survival (OS) in first-line therapy for Diffuse Large B-Cell Lymphoma (DLBCL): findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) analysis of individual patient data from 7507 patients. Blood. 2016;128(22):4196–4196.
   Web of Science ®Google Scholar